miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2

Human Cell

Volumn 28, Issue 2, 2015, Pages 91-99

  Zhao, Chunfang ^a   Li, Ya ^a   Zhang, Ming ^a   Yang, Yi ^a   Chang, Li ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Cell apoptosis; Cell cycle; Cell proliferation; Hepatocellular carcinoma; miR 126; Sox2

Indexed keywords

MICRORNA; MIRN126 MICRORNA, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; SOXB1 TRANSCRIPTION FACTORS;

EID: 84939966188     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-014-0105-z     Document Type: Article

References (30)

1. Worns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl 3):S302–9. doi:10.1016/s1590-8658(10)60521-x.
2. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44(Suppl 19):96–101. doi:10.1007/s00535-008-2258-6.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
4. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8(2):93–103. doi:10.1038/nrg1990.
5. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58. doi:10.1016/s1470-2045(12)70073-6.
6. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990). 2013. doi:10.1016/j.ejca.2013.06.002.
7. Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, et al. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene. 2013;527(1):26–32. doi:10.1016/j.gene.2013.06.006.
8. Saito Y, Hibino S, Saito H. Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Res. 2013;. doi:10.1111/hepr.12147.
9. Nikolic I, Plate KH, Schmidt MH. EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenesis Res. 2010;2(1):9. doi:10.1186/2040-2384-2-9.
10. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 2008;105(5):1516–21. doi:10.1073/pnas.0707493105.
11. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer (Amsterdam, Netherlands). 2009;66(2):169–75. doi:10.1016/j.lungcan.2009.01.010.
12. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008;135(1):257–69. doi:10.1053/j.gastro.2008.04.003.
13. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One. 2011;6(1):e16617. doi:10.1371/journal.pone.0016617.
14. Leonardo TR, Schultheisz HL, Loring JF, Laurent LC. The functions of microRNAs in pluripotency and reprogramming. Nat Cell Biol. 2012;14(11):1114–21. doi:10.1038/ncb2613.
15. Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood, NJ). 2013. doi:10.1177/1535370213497321.
16. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, et al. MiR-494 within an oncogenic MicroRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of MCC. Hepatology (Baltimore, MD). 2013. doi:10.1002/hep.26662.
17. Wang PY, Sun YX, Zhang S, Pang M, Zhang HH, Gao SY, et al. Let-7c inhibits A549 cell proliferation through oncogenic TRIB2 related factors. FEBS Lett. 2013;587(16):2675–81. doi:10.1016/j.febslet.2013.07.004.
18. Kogure T, Kondo Y, Kakazu E, Ninomiya M, Kimura O, Shimosegawa T. Involvement of miRNA-29a in epigenetic regulation of transforming growth factor-beta-induced epithelial–mesenchymal transition in hepatocellular carcinoma. Hepatol Res. 2013;. doi:10.1111/hepr.12188.
19. de Giorgio A, Castellano L, Krell J, Stebbing J. Crosstalk-induced loss of miR-126 promotes angiogenesis. Oncogene. 2013;. doi:10.1038/onc.2013.317.
20. Yin X, Li YW, Jin JJ, Zhou Y, Ren ZG, Qiu SJ, et al. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett. 2013;5(4):1155–62. doi:10.3892/ol.2013.1151.
21. Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, et al. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem. 2011;44(8–9):582–9. doi:10.1016/j.clinbiochem.2011.02.012.
22. Yuan H, Corbi N, Basilico C, Dailey L. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev. 1995;9(21):2635–45.
23. Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by So1–3 activity. Nat Neurosci. 2003;6(11):1162–8. doi:10.1038/nn1131.
24. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999;27(6):1409–20.
25. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5(1):e8960. doi:10.1371/journal.pone.0008960.
26. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16(12):3488–98. doi:10.1245/s10434-009-0617-z.
27. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol. 2011;3(4):230–8. doi:10.1093/jmcb/mjr002.
28. Sun C, Sun L, Li Y, Kang X, Zhang S, Liu Y. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol (Northwood, London, England). 2013;30(2):503. doi:10.1007/s12032-013-0503-1.
29. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, et al. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif. 2012;45(3):207–16. doi:10.1111/j.1365-2184.2012.00812.x.
30. Li N, Li X, Huang S, Shen S, Wang X. [miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene]. Zhong nan da xue xue bao Yi xue ban = J Cent South Univ Med Sci. 2013;38(8):809–17. doi:10.3969/j.issn.1672-7347.08.009.